Pacific Shuanglin Bio-pharmacy Hits Day Low Amid Price Pressure at CNY 11.34

Pacific Shuanglin Bio-pharmacy Co., Ltd. has experienced a notable decline today, with the stock dropping by 3.07% as it reached an intraday low of CNY 11.34. This performance contrasts sharply with the China Shanghai Composite, which has seen a modest increase of 0.4% on the same day. Over the past week, Pacific Shuanglin has faced a 4.53% decrease, while its one-month performance shows a slight gain of 1.61%. However, the longer-term outlook remains concerning, with a staggering 39.31% decline over the past year and a significant 65.39% drop over the last five years. The company's market capitalization stands at CNY 11,543 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology sector. Financial metrics indicate challenges, including a net sales decline of 8.47% and negative results reported for the last six consecutive quarters. The operating cash flow has reached a low of CNY -201.95 million, and the return on equity is recorded at 4.32%. These indicators reflect ongoing difficulties in maintaining a stable financial position in a competitive market.